TX-AG v. Tris Pharma

Tris Pharma and Tris CEO Ketan Mehta allegedly defrauded the Texas Medicaid program by making false statements in violation of the Texas Medicaid Fraud Prevention Act, now known as the Texas Health Care Program Fraud Prevention Act (“THFPA”). Tris manufactured a potent attention-deficit/hyperactivity disorder (“ADHD”) drug for children called Dyanavel XR and targeted Texas Medicaid with a fraudulent marketing scheme. Mehta and Tris pushed false claims that overstated Dyanavel’s efficacy. Tris directed their sales representatives to deliver false and misleading messages about Dyanavel to doctors in Texas, including Medicaid doctors. Sales representatives falsely told doctors that Dyanavel worked significantly faster than other drugs and provided other unproven benefits to pediatric patients, according to TX-AG.

Summary generated from official Texas Attorney General press release